EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Itraconazole (ITRA) with Standard Radiotherapy (RT) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) ITRA-RAD: Phase I Clinical Study

Dusan Milanovic, Tatiana Lushchaeva, Hai Minh Ha, Raul-Ciprian Covrig, Christian Scheller, Klaus-Peter Stein, I. Erol Sandalcioglu, Antje Wiede, André Glowka, Daniel Medenwald

Radiation · 02.06.2026 · 6 (2) · 19

DOI: 10.3390/radiation6020019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation, online erschienen am 02.06.2026. Verfasst von Dusan Milanovic und 9 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otto-von-Guericke-University Magdeburg Medical Faculty.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical studies and data from other cancers suggest that inhibition of the Hedgehog (Hh) pathway also has antiproliferative effects on glioma cells. A key component of this pathway is the Smoothened (SMO) protein, which is expressed in high-grade gliomas. Itraconazole (ITRA), a widely used antifungal agent, inhibits SMO, the PI3K/AKT/mTOR pathway, and the VEGF/VEGFR-2 axis—both of which are critical for GBM progression and angiogenesis. This protocol describes a prospective, single-center, dose-escalation phase I study with the classical 3 + 3 design in order to determine the MTD of ITRA. The study enrolls patients with a newly histologically confirmed diagnosis of GBM, without previous treatment except surgery. They will be treated with standard RT schedule (60 Gy in 30 fractions) with concurrent TMZ 75 mg/m2 and ITRA 2 × 100 mg, 200 mg, or 300 mg daily. The primary endpoint is to determine the MTD of ITRA given concurrently with RT + TMZ. Secondary endpoints include safety and tolerability of ITRA, overall survival (OS), progression-free survival (PFS), overall objective response rate, use of corticosteroids, treatment compliance, and health-related quality of life (EORTC QLQ-C30 and BN20). Participants will be monitored for one week post-treatment. All relevant statistics will be primarily descriptive.

Förderung

  • Otto-von-Guericke-University Magdeburg Medical Faculty

Zitieren

APA

Milanovic, D., Lushchaeva, T., Ha, H. M., Covrig, R., Scheller, C., Stein, K., Sandalcioglu, I. E., Wiede, A., Glowka, A., & Medenwald, D. (2026). Itraconazole (ITRA) with Standard Radiotherapy (RT) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) ITRA-RAD: Phase I Clinical Study. Radiation, 6(2), 19. https://doi.org/10.3390/radiation6020019

Vancouver

Milanovic D, Lushchaeva T, Ha HM, Covrig R, Scheller C, Stein K, et al. Itraconazole (ITRA) with Standard Radiotherapy (RT) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) ITRA-RAD: Phase I Clinical Study. Radiation. 2026;6(2):19. doi:10.3390/radiation6020019

BibTeX
@article{Milanovic2026,
  author = {Milanovic, Dusan and Lushchaeva, Tatiana and Ha, Hai Minh and Covrig, Raul-Ciprian and Scheller, Christian and Stein, Klaus-Peter and Sandalcioglu, I. Erol and Wiede, Antje and Glowka, André and Medenwald, Daniel},
  title = {Itraconazole (ITRA) with Standard Radiotherapy (RT) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) ITRA-RAD: Phase I Clinical Study},
  journal = {Radiation},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {19},
  doi = {10.3390/radiation6020019}
}
Kostenlos starten →